NORTH CHICAGO, Ill. - AbbVie (NYSE: ABBV), a global biopharmaceutical company, and EvolveImmune Therapeutics, a firm specializing in immunotherapy, have announced a collaboration to develop multispecific biologics targeting cancer. The partnership, which includes an option-to-license agreement, will utilize EvolveImmune's proprietary EVOLVE T-cell engager platform to create novel antibody-based therapies aimed at solid and hematologic malignancies.
The EVOLVE platform is engineered to enhance T-cell responses against tumors by providing potent, selective, and integrated co-stimulation, aiming to overcome the resistance often seen with current cancer immunotherapies. This collaboration is part of AbbVie's commitment to investing in innovative technologies to address unmet needs in cancer treatment.
Under the agreement, EvolveImmune will receive $65 million upfront in fees and equity investment from AbbVie. Additionally, the potential financial benefits for EvolveImmune could reach up to $1.4 billion in option fees and milestone payments, along with tiered royalties on net sales of any developed products.
Jonathon Sedgwick, Ph.D., Senior Vice President and Global Head of Discovery (NASDAQ:WBD) Research at AbbVie, expressed enthusiasm for the partnership, highlighting the potential of EvolveImmune's platform to advance cancer treatment. Stephen Bloch, M.D., CEO of EvolveImmune, also noted the significance of the collaboration with AbbVie, emphasizing the potential of their technology to provide clinically meaningful benefits to patients.
The collaboration is a strategic move for both companies, with AbbVie enhancing its oncology portfolio and EvolveImmune gaining validation and financial support for its platform. First-in-human clinical trials of the developed therapies are expected to begin in 2025.
AbbVie's oncology strategy involves a dynamic pipeline of investigational therapies, focusing on targeted treatments that impede cancer cell reproduction or enable their elimination. The company is evaluating over 20 investigational medicines in clinical trials for various cancers.
This news is based on a press release statement and contains forward-looking statements that involve risks and uncertainties. AbbVie has highlighted the potential for actual results to differ from those projected, citing challenges such as intellectual property disputes, competition, and research and development difficulties.
In other recent news, AbbVie Inc (NYSE:ABBV). has reported impressive financial performance, with BMO Capital Markets increasing the company's stock target due to better-than-expected quarterly results. The biopharmaceutical company's earnings report revealed a stronger quarter than anticipated, with products such as Skyrizi and Rinvoq performing well. AbbVie's management maintains a positive outlook, forecasting mid-single-digit growth in revenue and earnings for the year 2025.
In a recent earnings call, AbbVie announced a robust third quarter, with sales exceeding expectations and significant growth in key product segments, leading the company to increase its full-year revenue and earnings guidance. Despite a decline in Humira sales, growth was observed in immunology, oncology, and neuroscience segments. The company's Q3 revenues reached nearly $14.5 billion, with an operational growth of 4.9%. Adjusted earnings per share for the quarter were $3, surpassing guidance by $0.10.
These are the latest developments for AbbVie, which continues to show resilience and growth in key areas. The company raised its full-year revenue guidance by $500 million and adjusted EPS guidance to $10.90-$10.94. Sales of Skyrizi and Rinvoq are projected to exceed $17 billion, with strong demand driving growth. A dividend increase of 5.8% has also been announced, reflecting confidence in the company's long-term growth prospects.
InvestingPro Insights
AbbVie's collaboration with EvolveImmune Therapeutics aligns well with its strong market position and financial performance. According to InvestingPro data, AbbVie boasts a substantial market capitalization of $360.48 billion, reflecting its significant presence in the biotechnology sector. This is further supported by an InvestingPro Tip indicating that AbbVie is a prominent player in the industry.
The company's financial health is robust, with a revenue of $55.0 billion over the last twelve months as of Q2 2024. Despite a slight revenue decline of 1.83% during this period, AbbVie maintains a strong gross profit margin of 69.66%, showcasing its operational efficiency.
Investors should note that AbbVie has raised its dividend for 12 consecutive years, as highlighted by an InvestingPro Tip. This consistent dividend growth, coupled with a current dividend yield of 3.08%, may appeal to income-focused investors. The company's commitment to shareholder returns is further evidenced by its impressive one-year price total return of 47.94%.
While AbbVie is trading near its 52-week high, with its price at 99.1% of the 52-week high, the company's valuation metrics suggest a mixed picture. The P/E ratio (adjusted) of 28.09 for the last twelve months indicates that the stock may be trading at a premium compared to some peers. However, this could be justified by the company's strong market position and potential growth from collaborations like the one with EvolveImmune.
For investors seeking more comprehensive analysis, InvestingPro offers 13 additional tips for AbbVie, providing deeper insights into the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.